Amarin Corp Plc (AMRN)

[rosemountbomber]

Sleven, I hope it is a view that is dead wrong, but here is my thought process. 
First I need to say that this is Amarin, and for all the double digit years that I have been a shareholder only one or two positive things have ever happened to it. No need to elucidate all the bad luck, mismanagement, cutthroat competitors' attacks, that have beset us. 
We are talking EU here.  I believe the eligible population there for V's benefits wrt the CVD indication far outnumbers those for the indication that may come out from the EMT2 Leeds study.  The sp has not been rewarded for V's value there as a CVD med so how can I jump to the conclusion that it will for the cancer study.  Now, where my thought process could be grossly wrong is twofold:
First, the word cancer carries more heft and fear than CVD - heck almost everyone of age has CVD.  Secondly, there are not a bunch of markers that can be used to cause docs to prescribe V (unlike a high cholesterol test automatically makes the doc write a script for statins), but here if the specified cancer pops up and V turns up with great pfs numbers in the trial it could be one of the top things oncologists turn to.  
Ultimately who knows but just going by Amarin's track record and not wanting to get my hopes up too soon I will just wait to see